Institutional Repository of Vilnius University
Effects of statin treatment on pcsk9 and ldlr levels: potential use in combinatory treatment with crispr-cas9 methodologies /
Abstract
dc:descriptionCardiovascular disease remains the leading cause of death worldwide, with low-density lip-oprotein (LDL) cholesterol playing a major role in its onset and progression. Statins are the first-choice drugs for preventing cardiovascular diseases, primarily due to their effectiveness in lower-ing cholesterol levels and reducing the risk of heart attacks and strokes. This study explores the impact of lipophilic simvastatin and hydrophilic pravastatin on PCKS9 and LDLR expression, with the goal of identifying the most effective statin and the optimal concentration for the use in combination with CRISPR-Cas9 gene editing. Among the statins evaluated, the lipophilic simvas-tatin at a concentration of 25 µM demonstrated an effect on both PCSK9 and LDLR levels, with-out significantly influencing cell viability or inducing DNA damage and apoptosis. Based on these findings, 25 µM simvastatin has been selected for future combination therapy. This combination strategy may allow for lower statin doses, minimizing side effects while maintaining or even enhancing therapeutic benefits.
Degree
thesis:*- Grantor dc:publisher
- Institutional Repository of Vilnius University
- Year dc:date
- 2025
Author and committee
dc:creator, dc:contributor.*- Author dc:creator
-
- Glebavičiūtė, Goda,
Subjects
dc:subject × 1Rights
dc:rights- Statement dc:rights
-
- info:eu-repo/semantics/openAccess
- Language dc:language
- eng
Identifiers
dc:identifier.*- Repository record dc:identifier
- https://repository.vu.lt/VU:ELABAETD239024585&prefLang=en_US